Elequin Capital’s Theravance Biopharma TBPH Stock Holding History

Elequin Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7	Closed	–	–	668
2022 Q2	$0	Sell	7 -9	-56%	-$83	﹤0.01%	439
2022 Q1	$0	Buy	+16	New	+$157	﹤0.01%	339

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elequin Capital's TBPH Position: Q3 2022 in Review

Elequin Capital sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 7 shares.

Elequin Capital first reported a position in TBPH in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

Elequin Capital reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
Elequin Capital sold 7 Theravance Biopharma shares in Q3 2022.
Elequin Capital first reported a position in Theravance Biopharma in Q1 2022 and held it in 2 quarters.
Elequin Capital's Theravance Biopharma position peaked at $0 in Q2 2022.
123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on Elequin Capital's 13F filing for Q3 2022, filed 10 Nov 2022.